MedTrace Logo

D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights

NCT01037101 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-10-14

No results posted yet for this study

Summary

The study will determine the effects of D-Cycloserine (DCS) on fear reduction in patients diagnosed with phobia of heights (acrophobia) undergoing one session of three hours of virtual reality exposure therapy (VRET) or in vivo exposure therapy (IVET).

Conditions

  • Height Phobia

Interventions

BEHAVIORAL

In Vivo Exposure Therapy

Three hours of exposure therapy in a high place

BEHAVIORAL

Virtual Reality Exposure Therapy

Three hours of exposure therapy using a virtual reality system

DRUG

D-Cycloserine

50 mg of DCS administered 30 minutes before the session

DRUG

Placebo

50 mg placebo administered 30 minutes before the session

Sponsors & Collaborators

  • West Virginia University

    collaborator OTHER

  • University of Charleston

    collaborator OTHER

  • CAMC Health System

    lead OTHER

Principal Investigators

  • Cristian Sirbu, Ph.D. · CAMC Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037101 on ClinicalTrials.gov